Companies › Beijing Gene Key Life Technology
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GKL-006 Injection iNKT cell therapy (invariant natural killer T cell therapy) | – | Phase 2 | Hepatocellular Carcinoma (HCC); Advanced Pancreatic Cancer | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07713290 | GKL-006 Injection | Phase 1 | Hepatocellular Carcinoma (HCC) | Oncology | Nov 2026 |
| NCT07777211 | GKL-006 Injection | Phase 1 | Advanced Pancreatic Cancer | Oncology | Mar 2027 |
| NCT07209813 | GKL-006 Injection | Phase 2 | Hepatocellular Carcinoma (HCC) | Oncology | Sep 2027 |
No annotated target.
–
Hangzhou Converd Abscint NV/SA CNBG-Virogin Biotech (Shanghai) Stella Pharma Dendreon
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.